Neotropix was founded in late 2003 by pioneers
in the field of oncolytic viruses and the inventor of nine patents
in related fields. The company is dedicated to the development and
commercialization of virus-based therapies to treat cancer and other
diseases.
Neotropix began operations in 2005 to develop and commercialize
naturally derived, systemically deliverable oncolytic viruses for the
treatment of solid tumors. By applying its proprietary screening process,
called ViruScreen, to previously untapped viral resources, Neotropix
has uncovered at least 19 entirely novel oncolytic candidates.
